Loading...
•
Sep 30, 2024
Aura Biosciences Q3 2024 Earnings Report
Aura Biosciences reported financial results and business highlights for Q3 2024.
Key Takeaways
Aura Biosciences reported positive Phase 2 end-of-study data with Bel-sar in early-stage choroidal melanoma and the ongoing Phase 3 CoMpass trial recently received authorization to start enrolling patients in Europe. Multiple clinical complete responses were observed with a single low dose of Bel-sar in the ongoing Phase 1 trial in non-muscle invasive bladder cancer. The company's strong cash position is expected to support operations into 2H 2026.
Presented positive Phase 2 end of study data with Bel-sar in early-stage choroidal melanoma.
Received authorization to start enrolling patients in Europe in the ongoing Phase 3 CoMpass trial.
Observed multiple clinical complete responses with a single low dose of Bel-sar in ongoing Phase 1 trial in Non-Muscle Invasive Bladder Cancer (NMIBC).
Cash position is expected to support operations into 2H 2026.
Forward Guidance
Aura Biosciences believes its current cash and cash equivalents and marketable securities will fund operations into the second half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...